Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 116 participants.

Also called NCT07118449

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 116 participants (planned count) (from the registry)
Sponsor
XyloCor Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT07118449
  • EU CT 2025-521325-33-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07118449. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-27 (anticipated); primary completion 2026-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
Acronym
EXACT-CABG
Intervention (Drug)
XC001
Intervention (Drug)
A195/placebo
Lead sponsor
XyloCor Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07118449
Content hash
76c96f2563d8476bafcd22c9972de35345c8e71fffc71d4337cf659a2f0adc6b